CTLA4 and breast carcinoma: Another preclinical study investigated the ability of the CA4P analogue (Oxi4503) to improve the responsiveness to immune checkpoint inhibitors (ICIs, namely, PD-1, PD-L1, CTLA-4) of resistant murine mammary carcinoma (C3H) (3).